Effect of Probiotic on Gut Microbiota in Young Children With Functional Constipation

Min-Tze LIONG

Status and phase: Enrolling; Phase 2

Conditions: Functional Constipation in Children

Treatments: Dietary Supplement: Probiotic; Dietary Supplement: probiotic + lactulose; Dietary Supplement: Lactulose Oral Liquid Product

Study type: Interventional

Funder types: Other

Identifiers

NCT07360535

XHEC-C-2018-027

Details and patient eligibility

About

This study was a 28-day, open-label, randomized controlled trial involving infants and toddlers diagnosed with functional constipation. Participants were randomized to receive either Bifidobacterium longum subsp. longum Dipro-X, lactulose, or a combination of both. The primary clinical outcomes assessed were bowel movement frequency, stool consistency, and defecation difficulty. To investigate potential mechanisms, stool samples were collected pre- and post-intervention for 16S rRNA gene sequencing to analyze changes in gut microbiota composition and identify specific bacterial taxa associated with clinical improvements.

Full description

Functional constipation is a prevalent chronic gastrointestinal disorder with significant implications for pediatric health. Within the first year of life, many infants are affected, a figure that rises to over 10% annually. This condition not only diminishes the quality of life for infants and toddlers but also contributes to substantial healthcare costs. Early intervention is widely recognized as critical for improving treatment outcomes, underscoring the need for effective therapeutic strategies.

Growing evidence indicates that intestinal microbiota dysbiosis plays a key role in the pathogenesis of functional constipation. Studies have consistently reported reduced abundances of beneficial bacteria such as Lactobacillus and Bifidobacterium in affected individuals compared to healthy controls. These findings have spurred interest in microbiota-targeted interventions, particularly the use of Bifidobacterium, for managing constipation. Although current evidence-based guidelines do not uniformly recommend probiotics for infant constipation due to limited clinical data, their potential to restore microbial balance remains promising. Advances in genomic technologies have enabled more detailed investigations into strain-specific mechanisms, shifts in signature microorganisms, and associated symptomatic improvements, findings that may help bridge existing evidence gaps. While preclinical studies, such as those involving murine models, have shown that Bifidobacterium longum can alleviate constipation by enhancing intestinal barrier function, clinical evidence in pediatric populations remains scarce.

To address this, the present study was conducted as a randomized, open-label, three-arm controlled clinical trial. It aimed to evaluate the efficacy of Bifidobacterium longum subsp. longum Dipro-X, lactulose, and their combination in infants and toddlers with functional constipation. The study specifically assessed the intervention's effects on clinical symptoms, including defecation frequency and stool characteristics, and explored correlations between gut microbiota changes and symptom improvement. The results are intended to support the development of evidence-based, targeted microbial interventions for functional constipation in early childhood.

Enrollment: 150 estimated patients

Sex: All

Ages: Under 3 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• According to the diagnostic criteria of Rome IV, the following symptoms include at least 2 and last for at least 1 month:

  1. Defecation <= 2 times per week;
  2. have a history of fecal retention;
  3. There is a history of pain or difficulty in defecation;
  4. There is a history of expelling large pieces of feces;
  5. There is a large fecal mass in the rectum. At least 1 episode of incontinence per week after self-control of bowel movements; passing large pieces of stool that may clog the toilet;

• Term infants, gestational age from 37 to 42 weeks;

• Birth weight between 2500 - 4000g;

• 0-3 years old;

• Parents voluntarily defer major changes in infant feeding practices;

• Parents are willing and able to fill in diaries and questionnaires

Exclusion criteria

• Chronic diseases or major medical problems;
• Gastrointestinal organic diseases;
• Growth retardation;
• The mother or child of the breastfeeding child used antibiotics within 2 weeks before randomization and during the trial;
• Infants (in formula and/or supplements) or their mothers used probiotics within 2 weeks before randomization and during the trial;
• Has participated in other clinical trials;
• Food allergies cause constipation (such as milk, eggs and other foods)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

150 participants in 3 patient groups

Probiotic

Experimental group

Description:

Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1 × 10\^9 CFU/day)

Treatment:

Dietary Supplement: Probiotic

Lactulose

Active Comparator group

Description:

Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day

Treatment:

Dietary Supplement: Lactulose Oral Liquid Product

Probiotic+Lactulose

Active Comparator group

Description:

Daily 6-drops of Bifidobacterium longum subsp. longum Dipro-X in non-GMO corn starch as excipient, in medium-chain triglyceride oil (1 × 10\^9 CFU/day), plus Lactulose liquid (each 1ml contains 0.667g lactulose) 5ml/time, once a day

Treatment:

Dietary Supplement: probiotic + lactulose